SPECIALTY GUIDELINE MANAGEMENT

CAMCEVI (leuprolide mesylate)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. <u>FDA-Approved Indication</u> Camcevi is indicated for the treatment of adult patients with advanced prostate cancer.

B. <u>Compendial Use</u> Prostate Cancer

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

Prostate Cancer

Authorization of 12 months may be granted for treatment of prostate cancer.

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section II who are experiencing clinical benefit to therapy (e.g., serum testosterone less than 50 ng/dL) and who have not experienced an unacceptable toxicity.

IV. REFERENCES

- 1. Camcevi [package insert]. Durham, NC: Accord BioPharma Inc.; May 2021.
- 2. The NCCN Drugs & Biologics Compendium[®] © 2024 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed February 1, 2024.

Camcevi 4763-A SGM P2024.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

